Avmapki Fakzynja Co-Pack (avutometinib; defactinib) — United Healthcare
KRAS-mutated recurrent low-grade serous ovarian cancer
Initial criteria
- Diagnosis of recurrent low-grade serous ovarian cancer (LGSOC)
- AND Tumor is KRAS-mutated
- AND Patient has received prior systemic therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Avmapki Fakzynja Co-Pack therapy
Approval duration
12 months